Customer Center
Login | Register

NxTAG® Respiratory Pathogen Panel

NxTAG Technology

 
Syndromic Testing Made Easy

The NxTAG® Respiratory Pathogen Panel is a next generation closed tube, molecular assay with comprehensive coverage designed to improve your laboratory workflow and enable your laboratory to simultaneously detect 20 respiratory pathogens, accommodating the higher throughput required to respond to changes on demand.

 

The NxTAG Respiratory Pathogen Panel streamlines respiratory testing:

  • Gain confidence in your results with excellent clinical performance
  • Easily detect 20 important pathogens in a single test
  • Decrease your hands-on time and turnaround time with a quick, easy protocol
  • Run 1-96 samples at a time with scalable throughput
  • Select any number of targets within the panel to customize the assay

 

 

NxTAG Respiratory Pathogen Panel Targets
Viral Targets
Influenza A Rhinovirus/Enterovirus Adenovirus
Influenza A H1 Parainfluenza virus 1 Coronavirus HKU1
Influenza A H3 Parainfluenza virus 2 Coronavirus NL63
Influenza B Parainfluenza virus 3 Coronavirus 229E
Respiratory Syncytial Virus A Parainfluenza virus 4 Coronavirus OC43
Respiratory Syncytial Virus B Human Metapneumovirus Human Bocavirus
Bacterial Targets
Chlamydophila pneumoniae Mycoplasma pneumoniae

NxTAG® Respiratory Pathogen Panel (RPP) Workflow | Step 1: Add 1-96 extracted samples to pre-plated test wells. Step 2: Integrated multiplex PCR and bead hybridiation Step 3: Read on MAGPIX®
NxTAG® Respiratory Pathogen Panel Ordering Information
Luminex Online Order Management
Email: orders@luminexcorp.com
Phone: 1-512-336-3550
Toll Free: 1-866-401-5450
Fax: 1-512-219-0544
Fax (Europe, Middle East, India, Asia): +31 (0)73 800 1998
Product Name Kit Size Registration Status Part Number
NxTAG® Respiratory Pathogen Panel 96 Tests US-IVD I051C0447

NxTAG Respiratory Pathogen Panel Resources & Posters:

 

Note: Luminex manufactures and distributes products mentioned in the reference materials provided in this section. The reference materials may mention use of product that has not been approved or cleared by regulatory agencies in your region or territory. Luminex is providing reference materials for customer information and does not recommend using the product inconsistent with the product’s intended use and labeling.

 

Research Use Only*

 

Development of a Semi-Quantitative Women’s Health Bacterial Panel on the Luminex NxTAG PlatformPoster


Workflow Evaluation of the Luminex NxTAG Respiratory Pathogen Panel Poster


Luminex NxTAG Respiratory Pathogen Panel (RPP)(RUO): Performance Study on 200 Clinical Respiratory SamplesPoster


Assessment of a High Throughput Next Generation Multiplex Respiratory Pathogen PanelPoster


Automation of Luminex NxTAG Respiratory Pathogen PanelPoster


Evaluation of Luminex NxTAG Respiratory Pathogen Panel (RPP) on Nasopharyngeal SwabsPoster


Evaluation of the Luminex NxTAG Respiratory Pathogen PanelPoster


Performance Assessment of the Luminex NxTAG Respiratory Pathogen PanelPoster


* This product is for Research Use Only. Not for use in diagnostic procedures. Please contact Luminex at support@luminexcorp.com to obtain the appropriate product information for your country of residence.

 

 

In Vitro Diagnostic Use

 

NxTAG® Respiratory Pathogen Panel (US-IVD)Sales Sheet


NxTAG® Respiratory Pathogen Panel Summary of Antimicrobial TherapyFlyer


Comparison of Luminex NxTAG Respiratory Pathogen Panel (RPP) and CLART® PneumoVir for the Diagnosis of Respiratory Pathogens in Bronchoalveolar Lavage SamplesPoster


Performance Assessment of the Luminex NxTAG Respiratory Pathogen Panel in Clinical Testing at the National University Hospital, SingaporePoster


Assessment of Nasopharyngeal Swab Sample Stability for Use with Luminex NxTAG Respiratory Pathogen PanelPoster


Evaluation of the Multi-Site Reproducibility of the NxTAG Respiratory Pathogen PanelPoster


Development and Validation of Fragment and Sequencing Assays as Composite Comparator Method for NxTAG Respiratory Pathogen PanelPoster


Detection of Influenza A H1 Subtype, Parainfluenza Viruses, Coronaviruses, Adenovirus, Enterovirus D68, Chlamydophila Pneumoniae and Mycoplasma Pneumoniae with Luminex NxTAG Respiratory Pathogen Panel (For IVD Use) in Clinical and Contrived SpecimensPoster


A Multi-Center Clinical Evaluation of the Luminex NxTAG Respiratory Pathogen Panel (For IVD Use) in Patients with Signs and Symptoms of Respiratory Tract InfectionPoster


Workflow Study and Comparison for 4 Commercially Available Respiratory Virus Panel AssaysPoster


Evaluation of the Limit of Detection and Analytical Reactivity of the NxTAG Respiratory Pathogen PanelPoster


Analytical Specificity Evaluation of the NxTAG Respiratory Pathogen Panel AssayPoster

For In Vitro Diagnostic Use. Products are region specific and may not be approved in some countries/regions. Please contact Luminex at support@luminexcorp.com to obtain the appropriate product information for your country of residence.

Intended Use (US-IVD):

NxTAG® Respiratory Pathogen Panel is a qualitative test intended for use on the Luminex® MAGPIX® Instrument for the simultaneous detection and identification of nucleic acids from multiple respiratory viruses and bacteria extracted from nasopharyngeal swabs collected from individuals with clinical signs and symptoms of a respiratory tract infection. The organism types and subtypes detected by the test are Influenza A, Influenza A H1, Influenza A H3, Influenza B, Respiratory Syncytial Virus A, Respiratory Syncytial Virus B, Coronavirus 229E, Coronavirus OC43, Coronavirus NL63, Coronavirus HKU1, Human Metapneumovirus, Rhinovirus/Enterovirus, Adenovirus, Parainfluenza virus 1, Parainfluenza virus 2, Parainfluenza virus 3, Parainfluenza virus 4, Human Bocavirus, Chlamydophila pneumoniae, and Mycoplasma pneumoniae.

The test is indicated as an aid in the detection and identification of viral and bacterial agents causing respiratory tract infections in symptomatic adult and pediatric patients, who are either hospitalized, admitted to emergency departments or who are outpatients with suspected respiratory tract infection.

The results of this test should not be used as the sole basis for diagnosis, treatment, or other patient management decisions. Negative results in the setting of a respiratory illness may be due to infection with pathogens not detected by this test or lower respiratory tract infection that is not detected by a nasopharyngeal swab specimen. Positive results do not rule out co-infection with other pathogens. The agent detected may not be the definite cause of disease. The use of additional laboratory testing (e.g. bacterial and viral culture, immunofluorescence, and radiography) and clinical presentation must be taken into consideration in order to obtain the final diagnosis of respiratory tract infection.

Performance characteristics for influenza A were established using specimens obtained during the 2013/2014 and 2014/2015 influenza seasons when influenza A/H3 and A/H1 were the predominant influenza A viruses in circulation. When other influenza A viruses are emerging, performance characteristics may vary. If infection with a novel influenza A virus is suspected based on current clinical and epidemiological screening criteria recommended by public health authorities, specimens should be collected with appropriate infection control precautions for novel virulent influenza viruses and sent to state or local health departments for testing. Viral culture should not be attempted in these cases unless a BSL 3+ facility is available to receive and culture specimens.